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Abstract
Background:  Molecular genetic studies suggest the dopamine D1 receptor (D1R) may be
implicated in attention-deficit/hyperactivity disorder (ADHD). As little is known about the
potential motor role of D1R in ADHD, animal models may provide important insights into this
issue.
Methods: We investigated the effects of a full and selective D1R agonist, SKF-81297 (0.3, 3 and
10 mg/kg), on motor behaviour and expression of the plasticity-associated gene, c-fos, in habituated
young adult male Spontaneously Hypertensive Rats (SHR), the most commonly used animal model
of ADHD, and Wistar-Kyoto (WKY; the strain from which SHR were derived).
Results: SHR rats were more behaviourally active than WKY rats after injection with vehicle. The
0.3 mg/kg dose of SKF-81297 increased motor behaviour (locomotion, sifting, rearing, and sniffing)
in both SHR and WKY rats. Total grooming was also stimulated, but only in WKY rats. The same
dose increased c-fos mRNA expression in the piriform cortex of both strains. The 3 mg/kg dose
increased sifting and sniffing in both strains. Locomotion was also stimulated towards the end of
the testing period. The intermediate dose decreased total rearing in both strains, and produced a
significant increase in c-fos mRNA in the striatum, nucleus accumbens, olfactory tuberculum, and
in the cingulate, agranular insular and piriform cortices. The 10 mg/kg dose of SKF-81297 produced
a biphasic effect on locomotion, which was characterized by an initial decrease followed by later
stimulation. The latter stimulatory effect was more pronounced in SHR than in WKY rats when
compared to their respective vehicle-injected groups. The 10 mg/kg dose also stimulated sifting and
sniffing in both strains. Both the 3 and 10 mg/kg doses had no effect on total grooming. The 10 mg/
kg dose induced significantly higher levels of c-fos mRNA expression in the nucleus accumbens and
adjacent cortical regions (but not striatum) of SHR when compared to WKY rats.
Conclusion: The present results suggest a potential alteration in D1R neurotransmission within
the frontal-striatal circuitry of SHR involved in motor control. These findings extend our
understanding of the molecular alterations in SHR, a heuristically useful model of ADHD.
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Background
Attention-deficit/hyperactivity disorder (ADHD) is a com-
mon behavioural disorder of childhood onset that often
persists into adulthood. The neurobiology of ADHD is
not well understood, but there is converging evidence
implicating the catecholamine rich frontal-striatal cir-
cuitry [1]. Specifically, dysregulation of dopamine (DA)
has been hypothesized in ADHD based on the potent effi-
cacy of indirect dopaminergic agonists, such as methyl-
phenidate, supported by in vivo evidence that
methylphenidate effects are related to striatal occupancy
of the dopamine transporter (DAT), by increasing extra-
cellular dopamine levels in the striatum [2]. Molecular
genetic studies have also focused on hypothesized associ-
ations between various DA related genes and ADHD, with
mixed evidence regarding DAT1 and somewhat stronger
results with respect to DA receptors DRD4 and DRD5 [3].
In brain, DA effects are mediated through activation of
two distinct receptor families, referred to as the D1 (D1A/
D1 and D1B/D5) and the D2 (D2L/S, D3 and D4) classes
[4]. These receptors belong to the super-family of seven
transmembrane domain receptors, which exert their bio-
logical effects via G-protein-coupled intracellular signal-
ing pathways. The DA D1 receptors (D1R), which are
expressed highly in the striatum and prefrontal cortex
(PFC), may be particularly relevant for ADHD. These
receptors are crucial modulators of the motor and cogni-
tive functions mediated by the frontal-striatal circuitry
[5,6], functions which are impaired in patients with
ADHD. At the genetic level, preliminary evidence sup-
ports an association between ADHD and polymorphisms
in D1R [7,8] or in related proteins such as calcyon [9]. In
addition, D1R densities are elevated in the striatum and
nucleus accumbens of spontaneously hypertensive rats
(SHR) [10-12], the most commonly used genetic animal
model of ADHD [13] – which is consistent with the
hypothesis that D1R neurotransmission may be altered in
ADHD. Accordingly, we investigated potential alterations
in the motor stimulatory role of D1R in SHR, and in the
normotensive Wistar-Kyoto strain (WKY; from which SHR
were derived). For this purpose, we studied the motor
responses to the full and selective D1R agonist, SKF-
81297 (0.3, 3, and 10 mg/kg s.c.), and the expression of
the plasticity-associated gene, c-fos, in the striatum and
adjacent cortical structures, in habituated young male
SHR and WKY rats. SKF-81297 was selected since it
appears to be a highly selective D1R ligand in vivo, based
on on its lack of inhibition of midbrain DA neurons [14],
and its lack of response in DA D1 receptor-deficient
mutant mice following systemic administration [15].
Methods
Subjects
Young adult male SHR and WKY rats (Taconic, Hudson,
NY) were used. The animals arrived in the laboratory 1
week before the experiments (at 7 weeks of age) and were
housed in groups of four of the same strain in standard
plastic cages (Type IV Makrolon®), under controlled con-
ditions of light: dark cycle (12:12 h, lights on at 07:00 h).
Food and water were available ad libitum. The experiments
were approved by the local Committee on Ethics of Ani-
mal Experimentation, Veteran Affairs Medical Hospital,
Manhattan, NY.
General behavioural procedure
Testing took place between 900 and 1600 h under
dimmed light conditions. Animals were used only once to
avoid carry-over effects. Prior to testing, animals were
brought in their home cages to a room adjacent to the test-
ing room, where they were weighed. Care was taken to
minimize stress during transportation and handling. In
order to optimize detection of agonist-induced stimula-
tory effects, experiments were carried out in habituated
rats. Briefly, rats were removed from their home cage and
placed individually in clear plexi-glass observation cages
(48 × 48 cm) with wood shavings as bedding material for
a period of 1 hour. Immediately after the habituation
period, each rat received a single injection of either ago-
nist or vehicle and tested for 1 hour.
Behavioural assessment
Assessments of agonist-induced motor behaviour were
carried out using a rapid time-sampling behavioural
checklist technique, in a manner similar to that described
previously [16]. For this procedure the behaviour of each
rat was analyzed for 10-sec periods at 1-min intervals over
15 consecutive minutes using an ethologically based
behavioural checklist to allow the presence or absence of
the following individual behaviors (occurring alone or in
combination): sniffing (flaring of nostrils with movement
of vibrissae); locomotion (coordinated movement of all
four limbs producing a change in location); total rearing
(rearing of any form); rearing seated (front paws reaching
upwards with hind limbs on floor in sitting position);
rearing to wall (front paws reaching upwards onto or
towards a cage while standing on hind limbs); rearing free
(front paws reaching upwards away from any cage wall
while standing on hind limbs); sifting (short, exploratory-
type movements of the front paws through bedding mate-
rial on the cage floor); total grooming (grooming of any
form); stillness (motionless: awake with no behavioural
changes evident, or asleep). Levels of chewing (chewing
movements directed onto physical material, i.e., bedding
material and/or faecal pellets, without consumption) and
eating (chewing with consumption) were too low for
meaningful assessment. All behavioural assessments wereBehavioral and Brain Functions 2006, 2:18 http://www.behavioralandbrainfunctions.com/content/2/1/18
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performed during the 5-to-20-, 25-to-40-, and 45-to-60-
min time intervals after drug or vehicle administration.
Drug procedure
(+)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-
[1H]-3-benzazepine hydrobromide (SKF-81297, Research
Biochemical and International, Natrick, MA, USA) was
dissolved in isotonic saline (0.9% NaCl) vehicle. The drug
was freshly made for each trial. Subcutaneous (s.c.) injec-
tions were administered into the neck in doses of 0.3, 3.0
and 10 mg/kg. Drug doses were calculated as salt weight.
Probes and labeling
The c-fos mRNA was prepared from a 500 base pair long
PvuII fragment of the c-fos cDNA as described previously
[17]. The plasmid containing this cDNA fragment was lin-
earized with appropriate restriction enzymes. 35S-Uridine-
5'-triphosphate (UTP)-labeled RNA antisense and sense
probes were transcribed in vitro using the appropriate tem-
plate and phage RNA polymerase, purified using Probe
Quant G-50 microcolumns (Amersham, NJ, USA) and
checked in denaturing acrylamide gel.
Hybridization
Expression of c-fos mRNA in the striatum and adjacent
regions was investigated using in situ hybridization tech-
nique. Brains were rapidly dissected and frozen on dry ice.
Coronal sections (20μm) were prepared on a cryostat and
stored at -80°C until used. The in situ hybridization was
performed as follows. The frozen tissue sections were
fixed in cold 4% paraformaldehyde in 0.1 M sodium
phosphate buffer pH 7.4 (PBS), for 10 min. After washing
with PBS for 5 min, the sections were rinsed in DEPC-H20
(5 min) and deproteinated with 0.1 M HCl for 5 min.
They were then rinsed twice with PBS (3 min each) and
placed into 0.25% acetic anhydride in 0.1 M trieth-
anolamine (pH 8.0) for 20 min at room temperature;
washed twice in PBS (3 min each) and dehydrated in
70%, 80% and 100% (2 min each). Sections were air dried
and prehybridized (50% formamide, 50 mM Tris-HCl, pH
7.6, 25 mM ethylene-diamine-tetraacetate (EDTA), pH
8.0, 20 mM NaCl, 0.25 mg/ml yeast tRNA, 2.5 × Den-
hardt's solution) for 4 h at 55°C. After draining the prehy-
bridization buffer, sections were hybridized overnight
(14–16 h) in a humidified chamber at 55°C. For hybridi-
zation, labeled probe was diluted to a final concentration
of 0.5 × 106 cpm/200 μl containing 50% deionized forma-
mide (pH5), 0.3 M NaCl, 20 mM Tris-HCl (pH 7.6), 5
mM EDTA (pH 8.0), 10 mM PBS, 0.2 mM dithiothreitol,
0.5 mg/ml yeast tRNA, 0.1 mg/ml poly-A-RNA, 10% dex-
tran sulfate, 1× Denhardt's solution. After hybridization,
the slides were rinsed in 1 × standard saline citrate (SSC),
0.01% SDS (15 min); 1 × SSC, 0.01 % SDS (30 min); 50%
formamide/0.5 × SSC (1 h); 1 × SSC, 0.01 % SDS (15 min)
at 55°C with continuous shaking. The sections were then
treated with 1μg RNase A (Roche, Nutley, NJ, USA) in
RNase buffer (0.5 M NaCl, 10 mM Tris-HCl, 5 mM EDTA,
ph 8.0) for 1 h at 37°C. After two additional washes in 1
× SSC, 0.01% SDS for 30 min, the sections were dehy-
drated in ascending alcohol series and air dried. Sections
were placed against β-Max film (Amersham, NJ, USA) and
stored at room temperature for 2 to 3 days. Films were
developed in D19 developer for 2 min and in 1:5 dilution
of Amfix fixative for 5 min. Non-specific hybridization
was determined by incubating sections with the respective
35S-UTP-labelled sense cRNA probe for the above cDNA
under identical conditions to that of the antisense RNA
probe.
Quantification
Computerized quantifications of mRNA levels were per-
formed on film autoradiograms using an Epson Perfec-
tion 1250 scanner and NIH Image J version 1.29 (U.S.
National Institutes of Health). Before performing the
analysis the invert function of the program was used. In
this case higher values would mean more signal (0 =
black/minimum optical density and 255 = white/maxi-
mum optical density). Mean optical density was measured
in the striatum, nucleus accumbens, olfactory tubercle,
and various cortical regions including cingulate, agranular
insular, and piriform cortices at different rostral-caudal
levels. All comparisons between groups were made on sec-
tions hybridized together, under identical conditions and
exposed for the same time period to β-Max film (Amer-
sham, NJ, USA).
Statistical analysis
Behavioural data were analyzed using either repeated
measures analysis of variance (ANOVA; STRAIN × DOSE
as main factors) or factorial ANOVA following a square
root transformation, to allow examination of interaction
effects. Statistical analysis of mRNA expression was per-
formed using ANOVA and individual comparisons were
made using Bonferroni/Dunn test. For all analyses, signif-
icance was assigned at the P < 0.05 level. All data are pre-
sented as means ± S.E.M.
Results
Effects of SKF-81297 on motor behaviour
Locomotion
ANOVA of locomotion revealed significant main effects of
STRAIN [F(1,36) = 32.46, P < 0.0001], DOSE [F(3,36) =
5.98, P < 0.01], as well as a significant TIME × DOSE
[F(6,72) = 7.33, P < 0.0001] interaction. Thus, vehicle-
injected SHR displayed higher levels of locomotion than
vehicle-injected WKY rats throughout the testing period.
In both strains, the lowest dose (0.3 mg/kg) of SKF-81297
produced a significant increase (P < 0.05) in locomotion
during the 5-to-20-, and 25-to-40-min time intervals (see
Fig. 1). The intermediate dose (3 mg/kg) produced anBehavioral and Brain Functions 2006, 2:18 http://www.behavioralandbrainfunctions.com/content/2/1/18
Page 4 of 10
(page number not for citation purposes)
Effects of SKF-81297 on motor behaviour of SHR and WKY rats (values are shown as means ± S.E.M., n = 4–6 per each group) Figure 1
Effects of SKF-81297 on motor behaviour of SHR and WKY rats (values are shown as means ± S.E.M., n = 4–6 per each group). 
Doses are arrayed from vehicle to highest (0, 0.3, 3, and 10 mg/kg) for each strain from left to right. **P < 0.0001; * P < 0.05 
compared to vehicle group of the same strain.Behavioral and Brain Functions 2006, 2:18 http://www.behavioralandbrainfunctions.com/content/2/1/18
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increase in locomotion only during the 45-to-60-min
time interval in both strains. The higher dose (10 mg/kg)
produced a biphasic effect on locomotion in both strains,
which was characterized by an initial decrease during the
5-to-20-min interval followed by a significant stimulation
during the last interval (45-to-60-min time interval). The
later stimulatory effect was more pronounced (P < 0.05)
in SHR than in WKY rats when compared to their respec-
tive vehicle-injected groups (see Fig.1).
Sifting
ANOVA of sifting revealed a significant main effects of
STRAIN [F(1,36)= 6.67, P < 0.05], DOSE [F(3,36) = 17.16,
P < 0.0001], TIME [F(2,72) = 6.60, P < 0.05], and a signif-
icant TIME × DOSE [F(6,72) = 4.49, P < 0.0001] interac-
tion. The 0.3 mg/kg dose of SKF-81297 produced a
significant increase in sifting during the 25-to-40-min
interval in both SHR and WKY rats. The 3 and 10 mg/kg
doses also significantly increased sifting during the mid-
dle and last intervals (i.e., 25-to-40- and 45-to-60-min)
(see Fig. 1).
Sniffing
No significant main effects of STRAIN were found. How-
ever, there was a significant main effect of DOSE [F(3,36)
= 24.31, P < 0.0001], as well as a significant TIME × DOSE
[F(6,72) = 4.02, P < 0.01] interaction. SKF-81297 pro-
duced a significant dose- and time-dependent increase (P
< 0.05) in sniffing in both SHR and WKY rats (see Fig. 1).
Total rearing
ANOVA of total rearing revealed significant main effects
of STRAIN [F(1,36) = 21.61, P < 0.0001], DOSE [F(3,36)
= 22.05, P < 0.0001], and TIME [F(2,72)= 3.29, P < 0.05],
as well as significant DOSE × STRAIN [F(3,36) = 3.62, P <
0.05] and TIME × DOSE [F(6,72) = 4.49, P < 0.001] inter-
actions. Thus, vehicle-injected SHR displayed significantly
higher levels of total rearing than vehicle-injected WKY
rats (P < 0.05) (see Fig. 1). The 0.3 mg/kg dose of SKF-
81297 produced a significant increase in total rearing in
both strains during the 25-to-40-min interval (see Fig. 1).
The 3 and 10 mg/kg doses produced a significant decrease
in total rearing during the 5-to-20-, and 25-to-40-min
intervals in SHR and WKY rats (see Fig. 1). No significant
effects were found during the 45-to-60-min interval.
These effects of SKF-81297 on total rearing were mainly
due to changes in rearing to wall (data not shown).
Total grooming
ANOVA of total grooming revealed significant main
effects of DOSE [F(3,36) = 3.19, P < 0.05] and TIME
[F(2,72) = 4.00, P < 0.05], and a significant TIME × DOSE
[F(6,72) = 2.52, P < 0.05] interaction. The effects of SKF-
81297 on total grooming were only observed during the
5-to-20-min interval (see Fig. 1). Thus, the 0.3 mg/kg dose
produced a significant increase in total grooming in WKY
rats but had no significant effect in SHR. The 3 and 10 mg/
kg doses had a tendency to decrease total grooming in
SHR which did not reach significance.
Effects of SKF-81297 on c-fos mRNA
The expression of the plasticity gene-associated gene, c-fos,
was evaluated in the striatum and adjacent cortical regions
60 min after drug administration.
Striatum
Challenge with SKF-81297 had significant DOSE-depend-
ent effects in the rostral (F(3,36) = 35.93, P < 0.0001),
middle (F(3,36) = 97.37, P < 0.0001), and caudal (F(3,36)
= 87.82, P < 0.0001) striatum. Further post-hoc analysis
with Bonferroni/Dunn test showed that relative to vehi-
cle, both the 3.0 and 10 mg/kg doses produced a signifi-
cant (P < 0.001) increase in c-fos  mRNA expression,
especially in the dorsal striatum. ANOVA of rostral and
caudal striatum revealed no significant effects of STRAIN
or DOSE × STRAIN interaction. However, in the middle
striatum ANOVA revealed a significant STRAIN (F(1, 36)
= 7.63, P = 0.01) main effect and DOSE × STRAIN interac-
tion (F(3,36) = 3.86, P = 0.02), with the 10 mg/kg dose
inducing significantly higher levels of c-fos mRNA expres-
sion in WKY than in SHR rats (see Figs 2 and 3).
Nucleus accumbens
ANOVA revealed a significant main effect of DOSE
(F(3,36) = 74.13, P < 0.0001), and STRAIN (F(1,36) =
32.76, P < 0.0001), as well as a significant DOSE ×
STRAIN interaction (F(3,36) = 26.34, P < 0.0001) in the
shell of the nucleus accumbens. Further post-hoc analysis
revealed that relative to vehicle, both the 3.0 and 10 mg/
kg doses of SKF-81297 produced a significant increase (P
< 0.0001) in c-fos mRNA, with the 10 mg/kg dose induc-
ing significantly higher levels of c-fos mRNA expression in
SHR rats when compared to WKY rats (see Figs. 2 and 3).
Olfactory tuberculum
Similar to the nucleus accumbens, ANOVA of the olfac-
tory tuberculum revealed a significant effect of DOSE
(F(3,36) = 126.05, P < 0.0001), and STRAIN (F(3,36) =
10.70, P = 0.002), as well as a significant DOSE × STRAIN
interaction (F(3,36) = 9.42, P < 0.0001). Further post-hoc
analysis revealed that relative to vehicle, both 3.0 and 10
mg/kg doses of SKF-81297 produced a significant increase
(P < 0.0001) in c-fos  mRNA, with the 10 mg/kg dose
inducing significantly higher levels of c-fos mRNA expres-
sion in SHR rats when compared to WKY rats (see Figs. 2
and 3).
Cingulate cortex
ANOVA of the cingulate cortex revealed a significant main
effect of DOSE (F(3,36)= 35.41, P < 0.0001), and STRAINBehavioral and Brain Functions 2006, 2:18 http://www.behavioralandbrainfunctions.com/content/2/1/18
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(F(1,36) = 31.25, P < 0.0001), as well as a significant
DOSE × STRAIN interaction (F(3,36) = 22.20, P <
0.0001). Further post-hoc analysis revealed that relative to
vehicle, both the 3.0 and 10 mg/kg doses of SKF-81297
produced a significant increase (P < 0.0001) in c-fos
mRNA in this region, with the 10 mg/kg dose inducing
significantly higher levels of c-fos  mRNA expression in
SHR rats when compared to WKY rats (see Figs. 2 and 3).
Agranular insular cortex
Similar to the cingulate cortex, ANOVA of the agranular
insular cortex revealed a significant effect of DOSE
(F(3,36) = 190.12, P < 0.0001), and STRAIN (F(3,36) =
75.22, P = 0.002), as well as a significant DOSE × STRAIN
interaction (F(3,36) = 67.32, P < 0.0001). Further post-
hoc analysis revealed that relative to vehicle, both 3.0 and
10 mg/kg doses of SKF-81297 produced a significant
increase (P < 0.0001) in c-fos mRNA, with the 10 mg/kg
dose inducing significantly higher levels of c-fos mRNA
expression in SHR rats when compared to WKY rats (see
Figs. 2 and 3).
Piriform cortex
ANOVA of this region revealed a significant main effect of
DOSE (F(3,36) = 169.88, P < 0.0001), and STRAIN
(F(1,36) = 30.62, P < 0.0001), as well as a significant
DOSE × STRAIN interaction (F(3,36) = 29.86, P <
0.0001). Further post-hoc analysis revealed that relative to
vehicle, all doses (0.3, 3, and 10 mg/kg) of SKF-81297
produced a significant increase (P < 0.0001) in c-fos
mRNA in this region, with the 10 mg/kg dose inducing
significantly higher levels of c-fos  mRNA expression in
SHR rats when compared to WKY rats (see Figs. 2 and 3).
The mean ± S.E.M. values for SHR and WKY rats are as fol-
lows: 12 ± 2, 30 ± 4, 65 ± 14, 195 ± 12 and 10 ± 2, 33 ± 4,
82 ± 7, 79 ± 5, respectively, for isotonic saline vehicle, 0.3,
3, and 10 mg/kg of SKF-81297.
Discussion
The present study was undertaken to investigate potential
differences in the motor role of D1R in SHR as compared
to WKY rats. We analyzed the effects of a full and selective
D1-like receptor agonist, SKF-81297, on motor behaviour
using an ethologically based approach. In addition, we
Effects of SKF-81297 (0.3, 3, and 10 mg/kg) on c-fos mRNA expression in the striatum and cortex of SHR and WKY rats (val- ues are shown as means ± S.E.M., n = 4–6 per each group) Figure 2
Effects of SKF-81297 (0.3, 3, and 10 mg/kg) on c-fos mRNA expression in the striatum and cortex of SHR and WKY rats (val-
ues are shown as means ± S.E.M., n = 4–6 per each group). **P < 0.0001; * P < 0.05 compared to WKY rats of the same dose. 
For further details see the results section.
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evaluated its effects on the mRNA expression of the plas-
ticity-associated gene, c-fos, in the striatum and cortex. The
results suggest potential alterations in D1R neurotrans-
mission within the frontal-striatal circuitry of SHR that is
involved in motor control.
Previous studies have reported increased motor activity
(i.e., horizontal and vertical activity) resulting from vari-
ous D1-like receptor agonists in habituated rats, including
the prototypical partial agonist, SKF-38393 [18-20].
Recent studies using full and selective agonists (SKF-
81297, A-68930, and dihydrexidine) have revealed that
D1R may also mediate inhibitory effects, at least with
regard to motor activity under conditions of high baseline
activity (e.g., non-habituated condition and d-ampheta-
mine-induced hyperactivity) [21-24]. Importantly, the
motor inhibitory effects of these full D1-like receptor ago-
nists are not mediated by increases in stereotypy (e.g.,
grooming). Using an ethological approach, we confirm
and extend these findings in habituated SHR and WKY
rats. Similar to the effects of SKF-81297 in male Sprague-
Dawley rats [22], the 10 mg/kg dose of SKF-81297
induced a biphasic effect on locomotion, which was char-
acterized by an initial inhibition (i.e., during the 5-to-20-
min interval) followed by later stimulation (i.e., during
the 45-to-60-min interval) in SHR and WKY rats. The later
stimulatory effects were more pronounced in SHR than in
WKY rats. Consistent with our previous findings in male
Sprague-Dawley rats [22], the decrease in locomotion dur-
ing the initial inhibitory phase was not due to an increase
in rearing or grooming because these parameters were
reduced during this interval. This indicates that the initial
inhibitory effect of this dose is mediated by a general
decrease in locomotor drive. In contrast to previous obser-
vations in Sprague-Dawley rats, the intermediate dose (3
mg/kg) of SKF-81297 was less effective in stimulating
locomotion than the 10 mg/kg dose. However, the inter-
mediate dose was very effective in stimulating sifting and
sniffing in both strains. Similar to Sprague-Dawley rats,
the 0.3 mg/kg dose of SKF-81297 increased locomotion in
both strains during the initial time period of testing.
Because this lower dose also increased sniffing and rear-
Representative autoradiograms of c-fos mRNA expression at different rostra-caudal levels (from top to bottom) of the striatum  and adjacent cortical structures in SHR and WKY rats after vehicle or 10 mg/kg dose of SKF-81297 Figure 3
Representative autoradiograms of c-fos mRNA expression at different rostra-caudal levels (from top to bottom) of the striatum 
and adjacent cortical structures in SHR and WKY rats after vehicle or 10 mg/kg dose of SKF-81297. Coronal sections are 
marked "+" for anterior and "-" for posterior to bregma. STR, striatum; OT, olfactory tubercle; NAc, nucleus accumbens (shell 
region); AI, agranular insula cortex; Cg, cingulate cortex; Pir, piriform cortex.
Vehicle                      SKF-81297 (10 mg/kg)
WKY SHR                    WKY                SHR
+1.60 mm
+0.70 mm
-0.80 mm
STR
Pir
Cg
AI
OT
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ing, it would suggest that this low dose of SKF-81297
heightened exploratory activity in both SHR and WKY
rats.
In rodents, the meso-striatal and meso-limbic DAergic
pathways are known to modulate spontaneous and DA-
induced motor activity. In particular, descending influ-
ences from the nucleus accumbens via the ventral palli-
dum to the mesencephalic locomotor region provide a
link between limbic and motor regions [25]. Neuroana-
tomical studies have demonstrated that D1R are highly
expressed in the striatum, nucleus accumbens and olfac-
tory tubercle, with somewhat lower concentrations in the
frontal cortex [4]. Peripheral administration of a D1-like
receptor agonist is known to induce a robust expression of
immediate early genes (e.g., c-fos) in intact habituated
rats, especially in the nucleus accumbens, olfactory tuber-
cle and cortex [26]. This induction of striatal c-fos mRNA
occurs only in medium-sized spiny neurons and can be
dose-dependently correlated with increases in motor
activity. Moreover, bilateral intra-accumbal injection of
SKF-38393 induces a dose-related increase in motor activ-
ity [27]. In the present study, we also found a dose-
dependent induction of c-fos  mRNA in the striatum,
nucleus accumbens, olfactory tubercle, and various corti-
cal regions including cingulate, agranular insular, and pir-
iform cortices in SHR and WKY rats. Although there were
no strain differences in c-fos mRNA expression at the lower
doses (0.3 and 3 mg/kg) of SKF-81297, the effects of the
10 mg/kg dose were highly strain dependent. Thus, in the
shell of the nucleus accumbens (but not core region, data
not shown), olfactory tuberculum and cortex c-fos mRNA
expression was strikingly more pronounced in SHR than
in WKY rats. It is worthwhile noting that this high dose of
SKF-81297 (10 mg/kg) has failed to induce c-fos expres-
sion in the brain of D1R mutant mice (-/-) [28], whereas
their wild-type control mice showed induction of c-fos
and other transcription factors in the striatum neocortex,
and other brain sites as described for this and other D1-
like agonists in the rat. Moreover, D1R mutant mice do
not respond to the locomotor stimulatory effects of SKF-
81297 (see [15]). Thus, suggesting that the behavioural
and cellular effects of the 10 mg/kg dose of SKF-81297
observed in the present study are mediated via activation
of D1R.
The observed differences in c-fos mRNA expression
between SHR and WKY rats could be due to strain differ-
ences in D1R density. For example, several authors have
demonstrated increased expression of D1R binding sites
in cortex, striatum, nucleus accumbens, and olfactory
tuberculum of SHR [10-12], which could be a conse-
quence of disturbances in DA uptake, storage and/or
metabolism in SHR (see [29]). However, the observed
strain differences in c-fos  mRNA expression after SKF-
81297 cannot be ascribed entirely to differences in D1R
binding, because in the dorsal striatum c-fos  mRNA
expression (see above) was found to be more pronounced
in WKY rats than in SHR. Moreover, the greatest effect of
the 10 mg/kg dose of SKF-81297 on c-fos mRNA expres-
sion was observed in areas of the cortex that have lower
density of D1R [4]. Therefore, cortical changes in c-fos
mRNA expression could reflect downstream conse-
quences of striatal D1R activation since the striatum
receives input from (and sends reciprocal signals to) many
cortical areas ([6]). There are also other possibilities that
could explain the above behavioural differences and
changes in c-fos mRNA expression after SKF-81297. One
possibility is that there may be specific alterations at the
level of the D1R-coupling mechanisms in different
dopaminergic pathways in SHR. In the brain, D1R are
known to couple to Gs-like binding proteins, e.g., Golf-
alpha [30], thereby stimulating adenylyl cyclase activity.
Although D1R are highly expressed in the striatum,
nucleus accumbens, olfactory tubercle and PFC (albeit at
lower levels), there appears to be a clear segregation of
their down-stream pathways. Golf-alpha is expressed
highly in striatum, and is almost absent in PFC. The Gs-
alpha, by contrast, is expressed highly in PFC, while
nucleus accumbens and olfactory tubercle have both iso-
forms [30]. Recent studies examining the functional cou-
pling of D1R have found that Golf-alpha knockout mice
do not show motor stimulatory effects to either SKF-
81297 or the psychostimulant cocaine [30]. In addition,
these mice do not display cocaine-induced c-fos mRNA
expression in striatum. Alternatively, the above behav-
ioural and molecular differences between SHR and WKY
rats could be mediated by alterations in the expression of
calcyon, a DA D1R interacting protein (DRD1IP), which
shifts the effector coupling of D1R (i.e., from Gs to Gq cou-
pling) to stimulate a calcium signaling pathway, without
influencing the D1R-adenyl-cAMP pathway [31-33]. This
effect requires a priming step involving activation of het-
erologous Gq/11 protein-coupled receptors. Interestingly,
polymorphisms of DRD1IP have been associated with
both inattentive and hyperactive/impulsive subtypes of
ADHD [9]. The expression of calcyon mRNA in the rat
brain has been previously described in Sprague-Dawley
rats [34]. Calcyon is highly expressed in the medial PFC
and nucleus accumbens, with relatively low expression in
striatum. It has been suggested that calcyon may interact
with D5R, because it contains a region similar in sequence
to the core calcyon binding domain of D1R. Thus, altera-
tions in calcyon expression could affect the function of
both D1R and D5R. It is worthwhile noting that D5R
share high sequence homology and pharmacological pro-
file with D1R [4] and, therefore, could contribute to the
behavioural effects of SKF-81297. Further studies are
required to investigate whether there are alterations in theBehavioral and Brain Functions 2006, 2:18 http://www.behavioralandbrainfunctions.com/content/2/1/18
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D5R expression and/or coupling mechanisms of D1R in
SHR.
Grooming behaviour has long been associated with acti-
vation of D1-class receptors in brain [16,20]. Thus,
peripheral injection of DA D1-like receptor agonists elicits
grooming behaviour that can be blocked by a selective
D1-like receptor antagonist (SCH-23390). Moreover, con-
genic D1R knockouts (but not congenic D2R knockouts)
show attenuation in grooming behaviour [16]. It was orig-
inally assumed that D1R play an exclusive role in regulat-
ing grooming on the basis of their high expression
(relative to the D5R) in brain regions implicated in this
behaviour such as the dorsolateral striatum [35]. How-
ever, new findings indicate that both D1R and D5R
appear to be involved in the expression of grooming [16].
These findings are consistent with anatomical studies
demonstrating modest D5R expression in discrete areas of
the striatum, where they may play a role in processing sig-
nals relating to motor function. In the present study,
grooming was induced in WKY rats by the lowest dose of
SKF-81297 tested (0.3 mg/kg), similar to that reported
previously [19,22]. However, the same dose had no signif-
icant effects in SHR. The higher doses (3 and 10 mg/kg) of
SKF-81297 had no significant effects in WKY, but they had
a tendency to decrease grooming in SHR during the initial
testing interval. It is worthwhile mentioning that these
higher doses significantly stimulated other behaviors
(e.g., sifting, sniffing, rearing and locomotion) in SHR,
which may compete with the expression of other behav-
iors such as grooming. Previous studies on the effects of
SCH-23390, a selective D1-like receptor antagonist, on
novelty-induced grooming behaviour have shown that
SHR are less sensitive to the suppressive effects of this drug
when compared to WKY rats [36]. Taken together, the
results suggest a potential alteration in D1R/D5R neuro-
transmission in SHR possibly through primary effects
within the dorsal striatum, an area involved in grooming
behaviour.
To the best of our knowledge, this is the first study that has
investigated the effects of a full and selective D1-like
receptor agonist on motor behaviour of SHR and WKY
rats. However, recent studies have investigated the effects
of a cocktail of quinpirole, a DA D2-like receptor agonist,
and SKF-38393, a partial D1-like receptor agonist on jaw
movements in SHR and WKY rats [37,38]. These authors
found that with regards to jaw movements, postsynaptic
D2-like/D1-like receptors in SHR are hyposensitive when
compared to those of WKY rats. Others have demon-
strated that SHR are less sensitive to the motor stimulatory
effects of DA D2-like receptor agonists (e.g., LY141865) as
well as the mixed D1-like/D2-like receptor agonist, apo-
morphine [39]. Taken together with the present study, the
available data indicate: (i) potential disturbances not only
in D1R/D5R neurotransmission but also the D2-class of
receptors in SHR, and (ii) that DA D1-like/D2-like recep-
tors of SHR can be found in either hyper- or hyposensitive
states depending upon the specific motor behavioural
parameters studied. Thus, there may exist an imbalance
between DA D1- and D2- classes of receptors and/or
related intracellular signalling mechanisms in SHR in dis-
tinct neuronal microcircuits involved in motor control
[40].
Conclusion
In this study we analyzed the effects of a full and selective
D1-like receptor agonist, SKF-81297, on motor behaviour
of SHR and WKY rats. In addition, we evaluated its effects
on the mRNA expression of the plasticity-associated gene,
c-fos, in striatum and adjacent cortical areas. We found
that SHR were more sensitive to the locomotor stimula-
tory effects of SKF-81297 when compared to WKY rats,
especially at the highest dose tested (10 mg/kg). Interest-
ingly, the same dose of SKF-81297 induced a more pro-
nounced increase in c-fos  mRNA expression in cortical
areas and nucleus accumbens in SHR than in WKY rats,
but less in the dorsal striatum. In contrast, SHR were less
sensitive to the stimulatory effects of this drug on groom-
ing behavior. These results suggest a potential alteration
in D1R/D5R neurotransmission within the frontal-striatal
circuitry of SHR involved in motor control. Future work
should focus on further characterizing potential strain dif-
ferences in D1R/D5R receptor intracellular signaling
mechanisms and/or interacting proteins (e.g., calcyon) in
the mesolimbic, mesocortical, and nigrostriatal DA path-
ways, and how they may relate to hyperactivity, impulsiv-
ity and inattention of SHR. In addition, as previously
suggested by the dynamic developmental theory of
ADHD, it will be of great importance to investigate how
environmental factors (e.g., stress) modulate the above
DA pathways and expression of the behavioural deficits in
SHR [41].
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